Inclusion Criteria:

- Male and female adults with metastatic renal cell carcinoma

- Patients will have tumors that bear a clear cell component that comprises greater
than or equal to 50% of the tumor.

- Disease must be measureable in accord with RECIST 1.1 guidelines.

- Patients who have developed progressive disease or intolerance on treatment with
sorafenib, sunitinib, bevacizumab, or pazopanib over a 60 day period who have not
discontinued this therapy more than 100 days prior to study enrollment. Progressive
disease per RECIST 1.1 guidelines will be preferred

- Therapy with up to three prior systemic regimens will be allowed.

- Patients may have been treated with any of the following: sorafenib, sunitinib,
bevacizumab, pazopanib, temsirolimus, everolimus, interferon alpha, interleuken-2.

- Treatment with up to one priorregimen that included cytotoxiv chemotherapy will be
allowed.

- Patients may have been treated with more than 1 antiangiogenic therapy (e.g.,
patients may have been treated with both sorafenib and sunitinib or sunitinib and
bevacizumab, or sequential combinations that include pazopanib).

- Life expectancy of at least 3 months

- ECOG performance status of 0 or 1.

- Tumor tissue must be available for correlative studies.

- Patients must consent to allow the acquisition of FFPE material (block or unstained
slides) by study personnel for performance of correlative tissue studies.

Exclusion Criteria:

- Known brain metastases

- Prior therapy with brivanib, or anti-FGFR (fibroblast growth factor receptor)therapy.

- History of thrombotic or embolic events within the last six months such as a
cerebrovascular accident (including transient ischemic attacks), pulmonary embolism.

- Gastointestinal bleeding or any other hemmorrhage/bleeding event CTCAE version 4.0
Grade greater than 3 within 30 days prior to study entry.

- Uncontrolled or significant cardiovascular disease.

- QTc greater than 450 msec on two consecutive ECGs (Baseline ECG should be repeated if
QTc is found to be greater than 450 msec.).

- Active infection, less than 7 days after completing systemic antibiotic therapy.

- History of non-healing wounds or ulcers or bone fractures within 3 months of
fracture.

- Major surgical procedure, open biopsy, or significant traumatic injury less than 3
weeks prior to study enrollment or those who receive minor surgical procedures (e.g.
core biopsy or fine needle aspiration)within 1 week prior to study enrollment.

- Cytotoxic chemotherapy within 3 weeks, bevacizumab within 2 months, or radiation
therapy within 2 weeks, other targeted therapies (e.g., sorefenib, sunitinib,
temsirolimus, everolimus)within 2 days.

- Inability to swallow tabletsor untreated malabsorption syndrome.

- Pre-existing thyroid abnormality with thyroid function that cannot be controlled with
medication.

- History of HIV

- Patients with centrally cavitating lung lesions.

- Patients requiring therapeutic anticoagulation with warfarin at baseline. However,
prophylactic therapy with a low molecular weight heparin at baseline is acceptable.